Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 5, 2018, Pages

  Vigil, Adam ^a,d   Estélles, Angeles ^b,e   Kauvar, Lawrence M ^b   Johnson, Scott K ^c   Tripp, Ralph A ^c   Wittekind, Michael ^a,f  

^a ContraFect Corporation ^*  (United States)

^b Trellis Bioscience   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e Achaogen Inc   (United States)

^f Olympic Protein Technologies   (United States)

Author keywords

IBV; Influenza; Monoclonal antibodies

Indexed keywords

EPITOPE; HEMAGGLUTININ; HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; ENTROPY; GENE SEQUENCE; HUMAN; HUMAN CELL; INFLUENZA B; INFLUENZA B VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSIENT EXPRESSION; TRANSIENT TRANSFECTION; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; FEMALE; IMMUNOLOGY; ORTHOMYXOVIRUS INFECTION; PATHOGENICITY; SERODIAGNOSIS; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; EPITOPES; FEMALE; HEMAGGLUTININS; HUMANS; INFLUENZA B VIRUS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 85046022701     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02269-17     Document Type: Article

References (48)

1. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. 1990. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175:59–68. https://doi.org/10.1016/0042-6822(90)90186-U.
2. Kanegae Y, Sugita S, Endo A, Ishida M, Senya S, Osako K, Oya A. 1990. Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season. J Virol 64:2860–2865.
3. Ambrose CS, Levin MJ. 2012. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 8:81–88. https://doi.org/10.4161/hv.8.1.17623.
4. Heikkinen T, Ikonen N, Ziegler T. 2014. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clin Infect Dis 59:1519–1524. https://doi.org/10.1093/cid/ciu664.
5. Glezen WP, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. 2013. The burden of influenza B: a structured literature review. Am J Public Health 103: e43–e51. https://doi.org/10.2105/AJPH.2012.301137.
6. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. 2010. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28:2149–2156. https://doi.org/10.1016/j.vaccine.2009.11.068.
7. Tafalla M, Buijssen M, Geets R, Vonk Noordegraaf-Schouten M. 2016. A comprehensive review of the epidemiology and disease burden of influenza B in 9 European countries. Hum Vaccin Immunother 12: 993–1002. https://doi.org/10.1080/21645515.2015.1111494.
8. Filleul L, Ranoaritiana DB, Balleydier E, Vandroux D, Ferlay C, Jaffar-Bandjee MC, Jaubert J, Roquebert B, Lina B, Valette M, Hubert B, Larrieu S, Brottet E. 2016. A major impact of the influenza seasonal epidemic on intensive care units, Reunion, April to August 2016. Euro Surveill 21(47): pii30405. https://www.eurosurveillance.org/content/10.2807/15607917.ES.2016.21.47.30405.
9. van de Sandt CE, Bodewes R, Rimmelzwaan GF, de Vries RD. 2015. Influenza B viruses: not to be discounted. Future Microbiol 10: 1447–1465. https://doi.org/10.2217/fmb.15.65.
10. McCullers JA, Hayden FG. 2012. Fatal influenza B infections: time to reexamine influenza research priorities. J Infect Dis 205:870–872. https://doi.org/10.1093/infdis/jir865.
11. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, Kawakami C, Kiso M, Ito M, Hatakeyama S, Kawaoka Y. 2007. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 44:197–202. https://doi.org/10.1086/509925.
12. Cho A, Wrammert J. 2016. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Curr Opin Virol 17:110–115. https://doi.org/10.1016/j.coviro.2016.03.002.
13. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850–856. https://doi.org/10.1126/science.1205669.
14. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin O, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337:1343–1348. https://doi.org/10.1126/science.1222908.
15. McCutcheon KM, Gray J, Chen NY, Liu K, Park M, Ellsworth S, Tripp RA, Tompkins SM, Johnson SK, Samet S, Pereira L, Kauvar LM. 2014. Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets. MAbs 6:460–473. https://doi.org/10.4161/mabs.27760.
16. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265–273. https://doi.org/10.1038/nsmb.1566.
17. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Corne-lissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J. 2008. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM memory B cells. PLoS One 3:e3942. https://doi.org/10.1371/journal.pone.0003942.
18. Lee PS, Wilson IA. 2015. Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Curr Top Microbiol Immunol 386:323–341. https://doi.org/10.1007/82_2014_413.
19. Hamilton BS, Whittaker GR, Daniel S. 2012. Influenza virus-mediated membrane fusion: determinants of hemagglutinin fusogenic activity and experimental approaches for assessing virus fusion. Viruses 4:1144–1168. https://doi.org/10.3390/v4071144.
20. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, Perry KJ, Faynboym A, Ilhan M, Horowitz M, Horowitz L, Palese P, Bhatt RR, Lerner RA. 2008. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 105:5986–5991. https://doi.org/10.1073/pnas.0801367105.
21. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O’Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208:181–193. https://doi.org/10.1084/jem.20101352.
22. Nelson AL, Dhimolea E, Reichert JM. 2010. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767–774. https://doi.org/10.1038/nrd3229.
23. Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, Tripp RA, Walsh EE, Keyt BA, Kauvar LM. 2009. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 183:6338–6345. https://doi.org/10.4049/jimmunol.0901373.
24. Kauvar LM, Liu K, Park M, DeChene N, Stephenson R, Tenorio E, Ellsworth SL, Tabata T, Petitt M, Tsuge M, Fang-Hoover J, Adler SP, Cui X, McVoy MA, Pereira L. 2015. A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types. Antimicrob Agents Chemother 59:1558–1568. https://doi.org/10.1128/AAC.04295-14.
25. Estelles A, Woischnig AK, Liu K, Stephenson R, Lomongsod E, Nguyen D, Zhang J, Heidecker M, Yang Y, Simon RJ, Tenorio E, Ellsworth S, Leighton A, Ryser S, Gremmelmaier NK, Kauvar LM. 2016. A high-affinity native human antibody disrupts biofilm from Staphylococcus aureus bacteria and potentiates antibiotic efficacy in a mouse implant infection model. Antimicrob Agents Chemother 60:2292–2301. https://doi.org/10.1128/AAC.02588-15.
26. Ryser S, Estelles A, Tenorio E, Kauvar LM, Gishizky ML. 2017. High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals. PLoS One 12:e0181464. https://doi.org/10.1371/journal.pone.0181464.
27. Arvia R, Corcioli F, Pierucci F, Azzi A. 2014. Molecular markers of influenza B lineages and clades. Viruses 6:4437– 4446. https://doi.org/10.3390/v6114437.
28. Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Sasaki T, Nishimura M, Misaki R, Kuhara M, Boonsathorn N, Fujiyama K, Okuno Y, Nakaya T, Ikuta K. 2013. Human monoclonal antibodies broadly neutralizing against influenza B virus. PLoS Pathog 9:e1003150. https://doi.org/10.1371/journal.ppat.1003150.
29. Corti D, Lanzavecchia A. 2013. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705–742. https://doi.org/10.1146/annurev-immunol-032712-095916.
30. Noah DL, Hill H, Hines D, White EL, Wolff MC. 2009. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol 16:558–566. https://doi.org/10.1128/CVI.00368-08.
31. Niesen FH, Berglund H, Vedadi M. 2007. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2:2212–2221. https://doi.org/10.1038/nprot.2007.321.
32. Toughiri R, Wu X, Ruiz D, Huang F, Crissman JW, Dickey M, Froning K, Conner EM, Cujec TP, Demarest SJ. 2016. Comparing domain interactions within antibody Fabs with kappa and lambda light chains. MAbs 8:1276–1285. https://doi.org/10.1080/19420862.2016.1214785.
33. Timmerman P, Puijk WC, Meloen RH. 2007. Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology. J Mol Recognit 20:283–299. https://doi.org/10.1002/jmr.846.
34. Szretter KJ, Balish AF, Katz JM. 2006. Influenza: propagation, quantification, and storage. Curr Protoc Microbiol Chapter 15:Unit 15G.1.doi:https://doi.org/10.1002/0471729256.mc15g01s3.
35. Pica N, Iyer A, Ramos I, Bouvier NM, Fernandez-Sesma A, Garcia-Sastre A, Lowen AC, Palese P, Steel J. 2011. The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses. J Virol 85:12825–12829. https://doi.org/10.1128/JVI.05930-11.
36. Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P. 2015. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob Agents Chemother 59:4162–4172. https://doi.org/10.1128/AAC.00290-15.
37. Wittekind M, Vigil A. 1 August 2017.Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy.US patent 9,718,875 B2.
38. Francis T. 1960. On the doctrine of original antigenic sin. Proc Am Philos Soc 104:572–578.
39. Henry C, Palm AE, Krammer F, Wilson PC. 2018. From original antigenic sin to the universal influenza virus vaccine. Trends Immunol 39:70–79. doi: https://doi.org/10.1016/j.it.2017.08.003.
40. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521–530. https://doi.org/10.1016/j.coviro.2013.07.007.
41. Chai N, Swem LR, Reichelt M, Chen-Harris H, Luis E, Park S, Fouts A, Lupardus P, Wu TD, Li O, McBride J, Lawrence M, Xu M, Tan MW. 2016. Two escape mechanisms of influenza A virus to a broadly neutralizing stalk-binding antibody. PLoS Pathog 12:e1005702. https://doi.org/10.1371/journal.ppat.1005702.
42. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87:6542–6550. https://doi.org/10.1128/JVI.00641-13.
43. Ermler ME, Kirkpatrick E, Sun W, Hai R, Amanat F, Chromikova V, Palese P, Krammer F. 2017. Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model. J Virol 91:e00286-17. https://doi.org/10.1128/JVI.00286-17.
44. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, de Man M, Ding Z, Apetri A, Kukrer B, Sneekes-Vriese E, Tomkiewicz D, Laursen NS, Lee PS, Zakrzewska A, Dekking L, Tolboom J, Tettero L, van Meerten S, Yu W, Koudstaal W, Goudsmit J, Ward AB, Meijberg W, Wilson IA, Radosevic K. 2015. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349: 1301–1306. https://doi.org/10.1126/science.aac7263.
45. Shen C, Chen J, Li R, Zhang M, Wang G, Stegalkina S, Zhang L, Chen J, Cao J, Bi X, Anderson SF, Alefantis T, Zhang M, Cai X, Yang K, Zheng Q, Fang M, Yu H, Luo W, Zheng Z, Yuan Q, Zhang J, Wai-Kuo Shih J, Kleanthous H, Chen H, Chen Y, Xia N. 2017. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med 9:eaam5752. https://doi.org/10.1126/scitranslmed.aam5752.
46. Wohlbold TJ, Podolsky KA, Chromikova V, Kirkpatrick E, Falconieri V, Meade P, Amanat F, Tan J, ten Oever BR, Tan GS, Subramaniam S, Palese P, Krammer F. 2017. Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes. Nat Microbiol 2:1415–1424. https://doi.org/10.1038/s41564-017-0011-8.
47. Zhang J, Liu X, Bell A, To R, Baral TN, Azizi A, Li J, Cass B, Durocher Y. 2009. Transient expression and purification of chimeric heavy chain antibodies. Protein Expr Purif 65:77–82. https://doi.org/10.1016/j.pep.2008.10.011.
48. Ho D, Fletcher T, Ni JHT. 2013. Kinetic analysis of antibodies from different cultured media. BioPharm Int 55:48–51.